TY - JOUR
T1 - Interactive Associations of Neuropsychiatry Inventory-Questionnaire Assessed Sleep Disturbance and Vascular Risk on Alzheimer’s Disease Stage Progression in Clinically Normal Older Adults
AU - Bubu, Omonigho M.
AU - Williams, Ellita T.
AU - Umasabor-Bubu, Ogie Q.
AU - Kaur, Sonya S.
AU - Turner, Arlener D.
AU - Blanc, Judite
AU - Cejudo, Jaime Ramos
AU - Mullins, Anna E.
AU - Parekh, Ankit
AU - Kam, Korey
AU - Osakwe, Zainab T.
AU - Nguyen, Ann W.
AU - Trammell, Antoine R.
AU - Mbah, Alfred K.
AU - de Leon, Mony
AU - Rapoport, David M.
AU - Ayappa, Indu
AU - Ogedegbe, Gbenga
AU - Jean-Louis, Girardin
AU - Masurkar, Arjun V.
AU - Varga, Andrew W.
AU - Osorio, Ricardo S.
N1 - Publisher Copyright:
Copyright © 2021 Bubu, Williams, Umasabor-Bubu, Kaur, Turner, Blanc, Cejudo, Mullins, Parekh, Kam, Osakwe, Nguyen, Trammell, Mbah, de Leon, Rapoport, Ayappa, Ogedegbe, Jean-Louis, Masurkar, Varga and Osorio.
PY - 2021/12/10
Y1 - 2021/12/10
N2 - Background: To determine whether sleep disturbance (SD) and vascular-risk interact to promote Alzheimer’s disease (AD) stage-progression in normal, community-dwelling older adults and evaluate their combined risk beyond that of established AD biomarkers. Methods: Longitudinal data from the National Alzheimer’s Coordinating Center Uniform-Dataset. SD data (i.e., SD+ vs. SD-), as characterized by the Neuropsychiatric Inventory-Questionnaire, were derived from 10,600 participants at baseline, with at-least one follow-up visit. A subset (n = 361) had baseline cerebrospinal fluid (CSF) biomarkers and MRI data. The Framingham heart study general cardiovascular disease (FHS-CVD) risk-score was used to quantify vascular risk. Amnestic mild cognitive impairment (aMCI) diagnosis during follow-up characterized AD stage-progression. Logistic mixed-effects models with random intercept and slope examined the interaction of SD and vascular risk on prospective aMCI diagnosis. Results: Of the 10,600 participants, 1,017 (9.6%) reported SD and 6,572 (62%) were female. The overall mean (SD) age was 70.5 (6.5), and follow-up time was 5.1 (2.7) years. SD and the FHS-CVD risk-score were each associated with incident aMCI (aOR: 1.42 and aOR: 2.11, p < 0.01 for both). The interaction of SD and FHS-CVD risk-score with time was significant (aOR: 2.87, p < 0.01), suggesting a synergistic effect. SD and FHS-CVD risk-score estimates remained significantly associated with incident aMCI even after adjusting for CSF (Aβ, T-tau, P-tau) and hippocampal volume (n = 361) (aOR: 2.55, p < 0.01), and approximated risk-estimates of each biomarker in the sample where data was available. Conclusions: Clinical measures of sleep and vascular risk may complement current AD biomarkers in assessing risk of cognitive decline in older adults.
AB - Background: To determine whether sleep disturbance (SD) and vascular-risk interact to promote Alzheimer’s disease (AD) stage-progression in normal, community-dwelling older adults and evaluate their combined risk beyond that of established AD biomarkers. Methods: Longitudinal data from the National Alzheimer’s Coordinating Center Uniform-Dataset. SD data (i.e., SD+ vs. SD-), as characterized by the Neuropsychiatric Inventory-Questionnaire, were derived from 10,600 participants at baseline, with at-least one follow-up visit. A subset (n = 361) had baseline cerebrospinal fluid (CSF) biomarkers and MRI data. The Framingham heart study general cardiovascular disease (FHS-CVD) risk-score was used to quantify vascular risk. Amnestic mild cognitive impairment (aMCI) diagnosis during follow-up characterized AD stage-progression. Logistic mixed-effects models with random intercept and slope examined the interaction of SD and vascular risk on prospective aMCI diagnosis. Results: Of the 10,600 participants, 1,017 (9.6%) reported SD and 6,572 (62%) were female. The overall mean (SD) age was 70.5 (6.5), and follow-up time was 5.1 (2.7) years. SD and the FHS-CVD risk-score were each associated with incident aMCI (aOR: 1.42 and aOR: 2.11, p < 0.01 for both). The interaction of SD and FHS-CVD risk-score with time was significant (aOR: 2.87, p < 0.01), suggesting a synergistic effect. SD and FHS-CVD risk-score estimates remained significantly associated with incident aMCI even after adjusting for CSF (Aβ, T-tau, P-tau) and hippocampal volume (n = 361) (aOR: 2.55, p < 0.01), and approximated risk-estimates of each biomarker in the sample where data was available. Conclusions: Clinical measures of sleep and vascular risk may complement current AD biomarkers in assessing risk of cognitive decline in older adults.
KW - Alzheimer’s disease
KW - amnestic mild cognitive impairment
KW - biomarkers
KW - cardiovascular disease
KW - sleep disturbance
UR - http://www.scopus.com/inward/record.url?scp=85121860132&partnerID=8YFLogxK
U2 - 10.3389/fnagi.2021.763264
DO - 10.3389/fnagi.2021.763264
M3 - Article
AN - SCOPUS:85121860132
SN - 1663-4365
VL - 13
JO - Frontiers in Aging Neuroscience
JF - Frontiers in Aging Neuroscience
M1 - 763264
ER -